SGLT2 inhibitors are associated with reductions in epicardial adipose tissue volume and thickness: a meta-analysis
A diabetes drug reduces dangerous heart fat deposits through a novel mechanism, explaining broader cardiovascular benefits beyond blood sugar control.
A systematic review and meta-analysis of 11 studies (n=284 patients) demonstrated that SGLT2 inhibitors produce significant reductions in epicardial adipose tissue — a metabolically active cardiac fat depot — with consistent effects across all imaging modalities and modest reductions in BMI and systolic blood pressure. These findings provide a novel mechanistic explanation for the broad cardiovascular benefits of SGLT2i beyond glucose lowering and may inform targeted cardiometabolic risk management strategies.
What the study was
- Study design
- Systematic review and meta-analysis
- Population
- Patients treated with SGLT2 inhibitors for type 2 diabetes or cardiometabolic disease (11 studies)
- Sample size
- 284
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- International Journal of Obesity
Why it surfaced
PROSPERO-registered meta-analysis quantifying SGLT2i effect on a specific cardiometabolic endpoint (EAT) with mechanistic implications; Nat portfolio journal publication; n=284 small meta-analysis but multimodality consistent; subgroup dapagliflozin vs empagliflozin hypothesis-generating only
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.